Esmirtazapine

DRUG8 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

DyssomniasInsomniaMenopauseMental DisorderMental DisordersPostmenopausal SymptomsSleep Disorder, IntrinsicSleep Disorders

Phase 3

Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)

CompletedNCT00482612

Merck Sharp & Dohme LLCInsomnia

Start: 2006-12-07End: 2008-08-11Updated: 2018-10-03

A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707)

CompletedNCT00506389

Merck Sharp & Dohme LLCInsomnia

Start: 2007-06-06End: 2008-02-13Updated: 2018-10-02

Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)

CompletedNCT00535288

Merck Sharp & Dohme LLCMenopause, Postmenopausal Symptoms, Vasomotor Symptoms

Start: 2004-09-15End: 2006-01-15Updated: 2019-04-02

Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)

CompletedNCT00560833

Merck Sharp & Dohme LLCMenopause, Vasomotor Symptoms

Start: 2004-10-15End: 2006-01-15Updated: 2019-04-02

Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)

CompletedNCT00561821

Merck Sharp & Dohme LLCDyssomnias, Insomnia, Mental Disorders +2

Start: 2007-11-20End: 2009-12-21Updated: 2018-10-03

A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001)

CompletedNCT00561574

Merck Sharp & Dohme LLCDyssomnias, Mental Disorder, Sleep Disorder, Intrinsic +2

Start: 2008-01-09End: 2010-02-14Updated: 2021-01-27

A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)

CompletedNCT00631657

Merck Sharp & Dohme LLCDyssomnias, Mental Disorders, Sleep Disorder, Intrinsic +2

Start: 2008-03-04End: 2009-11-19Updated: 2018-10-02

Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007)

TerminatedNCT00750919

Merck Sharp & Dohme LLCDyssomnias, Mental Disorders, Sleep Disorders +2

Start: 2008-10-07End: 2010-03-10Updated: 2021-02-02

Related Papers

Efficacy and safety of esmirtazapine in adult outpatients with chronic primary insomnia: a randomized, double-blind placebo-controlled study and open-label extension.

2020-09-0110 citations

Esmirtazapine treatment of postmenopausal vasomotor symptoms: two randomized controlled trials

Climacteric2019-02-046 citations